An interventional study of Lateral Extra-Articular Tenodesis (LET) and ACL Reconstruction in LET, ACL Reconstruction and Osteoarthritis (OA) of the Knee, sponsored by Western University, Canada. Enrolling by invitation at 8 sites in 2 countries. Open to participants aged 14 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-05-14.
Sponsored by Western University, Canada · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 205 studies in Osteoarthritis with a site in Canada — 25 open to participants now, 46 under way, 4 of them phase 3. Osteoarthritis · Canada.
Among the 205 studies in Osteoarthritis with a site in Canada, this one is the 20th largest by planned enrollment of the 176 interventional ones that give a count, is one of 4 that started in 2024, is one of 101 with no phase, reaches primary completion later than 19 of the 45 other live ones, and was the 194th registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →25 of the 205 studies in Osteoarthritis with a site in Canada are open now. Recruiting first, the newest first:
Pfizer · Sites in Canada, United States
Ages 18+
FUSMobile Inc. · Sites in Canada
Ages 18+
University of British Columbia · Sites in Canada
Ages 50+
St. Joseph's Healthcare Hamilton · Sites in Canada
Ages 18+
Eli Lilly and Company · Sites in Canada, United States, Argentina and 10 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 14 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
205 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 32 · Phase 3 31 · Phase 4 13
First in 1996; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 510 is above the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 98 across the 176 interventional studies, 132 across the 29 observational. Of the 130 that completed or were terminated, 37 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
77 of 205 have an industry lead sponsor. The 10 most frequent:
Western University, Canada is the lead sponsor of 224 studies on the registry; 56 are open to participants now.
Western University, Canada has 8 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
15 of the studies in Osteoarthritis with a site in Canada that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06966206Phase 3St. Joseph's Healthcare HamiltonMultiprofen-CC to Reduce Pain in Hand Arthritis | 2026-12-31 |
| NCT03626038Zimmer BiometPost Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System | 2026-12 |
| NCT04634773Ottawa Hospital Research InstituteUnravelling the Etiology of Shoulder Osteoarthritis | 2026-12 |
| NCT06681142University of AlbertaPharmacist-physiotherapist Collaborative Management for Early Knee Osteoarthritis | 2026-12-01 |
| NCT07178951FUSMobile Inc.Neurolysis for the Treatment of Medial Chronic Knee Pain Due to Osteoarthritis | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 205 studies in Osteoarthritis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
From 2014-2017, across 7 Canadian and 2 European sites, we randomized 618 patients at high-risk of re-injury, to anterior cruciate ligament reconstruction (ACLR) with or without a lateral extraarticular tenodesis (LET) and demonstrated that the addition of the LET reduced the risk of instability (RRR=0.38; 95% Confidence Interval (CI), 0.21-0.52; P=0.0001) and graft re-rupture (RRR, 0.67; 95% CI, 0.36-0.83; P=0.001). As a result, practice has changed; there has been a large increase in the proportion of orthopaedic surgeons recommending the addition of an LET at the time of ACLR and an increase in the number of patients requesting an LET from their surgeon. There is some weak evidence suggesting that in the longer term, the LET may increase the risk of developing osteoarthritis (OA) in that knee. Knee OA affects over 4.4 million Canadians and the number of younger adults being diagnosed with knee OA is growing and is a primary reason for seeking healthcare in Canada. The impact of OA in Canada is enormous and projected to cost Canada $17.5 billion annually in lost productivity alone by 2031. This study will use imaging and patient-reported Knee Outcomes Osteoarthritis Score (KOOS) to evaluate the incidence of OA at 10-years post ACL reconstruction with and without LET. We will also collect information about overall knee health, patient-reported outcomes, costs associated with knee injury, rehabilitation and disability, clinical failure, functional ability, and sport participation. It is crucial that we understand the risks of developing knee OA associated with the addition of an LET to an ACLR so that surgeons and patients can make informed decisions, not just for their immediate post injury treatment of the failed ligament, but for the potential long-term consequences of that decision.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
2 or more of:
Exclusion criteria:
Standard ACL reconstruction only.
Procedure: ACL Reconstruction
Anatomic ACL reconstruction following the same procedure as the active comparator group with an added lateral extra-articular tenodesis (LET).
Procedure: Lateral Extra-Articular Tenodesis (LET) · Procedure: ACL Reconstruction
Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith \& Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
Lateral compartment knee OA
As was conducted at baseline and two years postoperative in the Stability 1 study, patients will undergo a standing semi-flexed posterior to anterior (PA) radiograph of both knees.
Time frame: 10 Years
Region-specific quality of life using the Knee Osteoarthritis and outcomes Score (KOOS)
The KOOS is a 42-item knee-specific questionnaire with five separately reported domains, including pain (9 items), other symptoms (7 items), function in daily living (17 items), function in sports/recreation (5 items) and knee-related quality of life (4 items). Domain scores represent the average of all items in the domain standardized to a score from 0 to 100 (worst to best). This instrument has face validity and has demonstrated construct validity, excellent test-retest reliability for each domain (range, 0.75 to 0.93) and has been shown to be responsive to change in patients undergoing ACLR.
Time frame: 10 Years
Disease-specific quality of life using the ACL Quality of Life Questionnaire (ACL-QOL)
The ACL-QOL has five domains that query physical symptoms, occupational concerns, recreational activities, lifestyle, and social and emotional aspects. Each item has one 100 mm visual analogue scale response option, with labeled anchors at 0 mm (e.g., extremely difficult) and 100 mm (e.g., not difficult at all). Scores are calculated by converting the average of each of the five domain scores to a total average score out of 100% where 100% represents the best possible score.
Time frame: 10 Years
The Marx Activity Rating Scale (MARS)
The MARS Activity Rating Scale is a four-item activity rating scale. The patient is asked to rate how often they were able to perform each activity (e.g. running, cutting, decelerating, and pivoting) in their most healthy and active state. The patient is provided with five categories of frequency of each functional activity, ranging from less than one time in a month to four or more times in a week. One point is allocated for each category of frequency and a maximum score of 16 points can be awarded. The MARS has demonstrated excellent test-retest reliability and construct validity in patients with disorders of the knee.
Time frame: 10 Years
Subjective symptoms, function and activity (IKDC)
The International Knee Documentation Committee Subjective Knee Form (IKDC) is a knee-specific functional outcome that consists of 18-items about symptoms (7 items), sports activities (10 items) and function (1 item). Likert scales, a dichotomized item and 11 point rating scales make up the response options, and total score ranges from 0 (total limitation) and 100 (no limitations). The IKDC has shown test-retest reliability and good construct validity in patients with issues at the knee.
Time frame: 10 Years
MRI
MRI will be performed only on patients recruited from the lead site at the Fowler Kennedy Sport Medicine Clinic (n=196). Similar to the imaging protocol used at the two-year visit, patients will undergo bilateral 3 Tesla MRI on a Siemens Magneton Trio magnet, and a 15-channel Siemens PRISMA knee coil at the 10-year visit. Longer T1rho and T2 relaxation times have shown to be associated with worsening cartilage quality. These changes can also be seen prior to the development of radiographic changes of OA, therefore, MRI can be used as a method for early detection of degenerative changes. The high incidence of arthritic changes observable at the 10 year time point using MRI (compared to plain radiographs), justifies the use of MRI in the subgroup of patients at the lead site.
Time frame: 10 Years
Patient Reported Quality of Life (ACL QOL)
The ACL-QOL has five domains that query physical symptoms, occupational concerns, recreational activities, lifestyle, and social and emotional aspects. Each item has one 100 mm visual analogue scale response option, with labeled anchors at 0 mm (e.g., extremely difficult) and 100 mm (e.g., not difficult at all). Scores are calculated by converting the average of each of the five domain scores to a total average score out of 100% where 100% represents the best possible score. The ACL-QOL has demonstrated validity in patients with ACL injury and responsiveness to change in patients following ACLR.
Time frame: 10 Years
4-Item Pain Intensity Measure (P4)
Four-item questionnaire that asks patients to report the amount of pain they experience throughout the day (morning, afternoon, evening) and with activity. Each item response is a visual analog scale ranging from 0 (no pain) to 10 (as bad as it can be). The total score is a sum of the four responses to a maximum score of 40. The P4 has demonstrated good test-retest reliability and the ability to detect changes in pain intensity in patients with muscle and joint injuries. Because men and women may experience and report pain differently, we have included the Gender Role Expectation of Pain questionnaire to examine its association with pain and quality of life reporting in this study.
Time frame: 10 Years
Clinical Failure
As previously described, clinical failure is defined as a composite of symptomatic instability requiring revision ACL surgery, or symptomatic instability with positive pivot shift, or asymmetrical pivot shift greater than the contralateral side.
Time frame: 10 Years
Objective Functional Measures
Range of motion (ROM) measurement will include passive knee extension and active-assisted knee flexion. For passive knee extension, the patient is seated with legs extended on a table, heel propped so that the calf and upper thigh clear the treatment table. We will instruct the patient to relax both quadriceps and hamstrings to assure passive measurement. For active assisted knee flexion, the patient is seated with both legs extended on a table. We will instruct them to perform active-assisted knee flexion by placing one hand under their thigh to initiate flexion and then clasp both hands just below the tibial tuberosity. We will measure flexion and extension in degrees using a goniometer. For both measurements, we will centre the fulcrum of the goniometer over the lateral epicondyle of the femur. We will then align the stationary arm of the goniometer with the greater trochanter of the femur and the moving arm with the lateral malleolus at the ankle.
Time frame: 10 Years
Adverse Events
We will record adverse events including painful hardware, graft rupture, and reasons for re-operation (e.g., painful knee joint, meniscal injuries, ACLR revision, contralateral ACLR, etc.). Given the significance of these types of events, we expect excellent recall.
Time frame: 10 Years
Started Nov 2024 (actual). Primary completion is estimated for Mar 2027, 28 months after the start.
Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 28 months is close to that.
Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.